

1 **A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for**  
2 **the treatment of post kala-azar dermal leishmaniasis.**

3

4 Brima M. Younis<sup>1</sup>, Rebecca Wiggins<sup>2</sup>, Eltahir A.G. Khalil<sup>1</sup>, Mohamed Osman<sup>2</sup>, Francesco  
5 Santoro<sup>3</sup>, Chiara Sonnati<sup>3</sup>, Ada Keding<sup>4</sup>, Maria Novedrati<sup>3</sup>, Giorgio Montesi<sup>3</sup>, Ali  
6 Noureldein<sup>1</sup>, Elmukashfi T. A. Elmukashfi<sup>1</sup>, Ala Eldin Mustafa<sup>1</sup>, Mohammed Alamin<sup>1</sup>,  
7 Mohammed Saeed<sup>1</sup>, Khalid Salman<sup>1</sup>, Ahmed J. Suliman<sup>1</sup>, Amin E.A. Musa<sup>1</sup>, Alison M.  
8 Layton<sup>2</sup>, Charles J. N. Lacey<sup>2\*</sup>, Paul M. Kaye<sup>2\*§</sup> and Ahmed M. Musa<sup>1\*§</sup>.

9

10 <sup>1</sup>Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University  
11 of Khartoum, Sudan

12 <sup>2</sup>York Biomedical Research Institute, Hull York Medical School, University of York,  
13 Heslington, York, UK

14 <sup>3</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy

15 <sup>4</sup>Department of Health Sciences, University of York, Heslington, York, UK

16

17 \* These authors contributed equally to the work

18 § **Correspondence** should be addressed to PMK ([paul.kaye@york.ac.uk](mailto:paul.kaye@york.ac.uk)) or AMM  
19 ([ahmed.musa@uofk.edu](mailto:ahmed.musa@uofk.edu))

20

21 **Short title:** Phase IIb leishmaniasis vaccine trial.

22

23 Key words: *Leishmania*, post kala azar dermal leishmaniasis, vaccine, therapeutic,  
24 adenovirus, clinical trial.

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 26 **Summary**

27 **Background.** In a recent Phase IIa clinical trial, the candidate leishmaniasis vaccine  
28 ChAd63-KH was shown to be safe and immunogenic in Sudanese patients with post kala-  
29 azar dermal leishmaniasis (PKDL). However, its value as a stand-alone therapeutic was  
30 unknown.

31 **Methods.** To assess the therapeutic efficacy of ChAd63-KH, we conducted a “window of  
32 opportunity” randomized, double-blind, placebo-controlled trial (Clinicaltrials.gov  
33 registration: NCT03969134). We aimed to enrol 100 participants (male and female aged 12-  
34 50 years) with uncomplicated PKDL of  $\geq$  six months duration. ChAd63-KH ( $7.5 \times 10^{10}$  viral  
35 particles) or saline placebo was administered once intramuscularly. Primary outcomes were  
36 safety and efficacy. Safety was determined by adverse event monitoring. Efficacy was the  
37 proportion of participants at 90 days post-vaccination with  $\geq 90\%$  improvement in clinical  
38 disease. Participants failing to reach this clinical endpoint were offered a standard of care  
39 (AmBisome<sup>®</sup>). Secondary outcomes included changes in PKDL severity grade and  
40 measurements of vaccine-induced immune response.

41 **Findings.** Between 4<sup>th</sup> April 2020 and 17<sup>th</sup> June 2022, 86 participants (66 adolescents, 20  
42 adults; 47% female, 53% male) were enrolled and randomised to receive ChAd63-KH or  
43 placebo. 75 participants (87%) completed the trial as per protocol. No severe or serious  
44 adverse events were observed. At day 90 post vaccination, 6/40 (15%) and 4/35 (11%)  
45 participants in the vaccine and placebo groups respectively showed  $\geq 90\%$  clinical  
46 improvement (RR 1.31 [95% CI, 0.40 to 4.28],  $p=0.742$ ). There were also no significant  
47 differences in PKDL grade between study arms. Whole blood transcriptomic analysis  
48 identified transcriptional modules associated with interferon responses and monocyte and  
49 dendritic cell activation, confirming vaccine reactogenicity.

50 **Interpretation.** Single dose administration of ChAd63-KH vaccine had no therapeutic  
51 efficacy in this subset of Sudanese PKDL patients. Further studies are needed to evaluate  
52 whether this vaccine would have therapeutic benefit using alternate dosing regimens or in  
53 combination with standard chemotherapy or immune modulation, and whether it has efficacy  
54 as a prophylactic vaccine for cutaneous or visceral leishmaniasis.

55 **Funding.** This study was funded by the Wellcome Trust.

56

## 57 **Research in context**

### 58 **Evidence before this study.**

59 A leishmaniasis vaccine candidate was developed employing chimpanzee adenovirus 63  
60 (ChAd63) to deliver genes encoding two *Leishmania* antigens, KMP-11 and HASPB1. This  
61 vaccine (ChAd63-KH) was previously evaluated for safety and immunogenicity in a Phase I  
62 healthy volunteer study and a Phase IIa study in Sudanese patients with post kala-azar dermal  
63 leishmaniasis (PKDL). It was shown to be safe and immunogenic, warranting further clinical  
64 studies to evaluate efficacy as a stand-alone therapeutic in PKDL patients.

### 65 **Added value of this study.**

66 This clinical trial was designed to evaluate the safety and efficacy of ChAd63-KH in PKDL  
67 patients with persistent disease (dermal lesions for  $\geq 6$  months). If successful, single dose  
68 vaccination would significantly improve treatment options currently available to patients.

69 The safety of ChAd63-KH was confirmed, with no severe or serious adverse events observed  
70 in trial participants. Approximately 13% of participants had  $\geq 90\%$  improvement in their  
71 PKDL over the course of 90 days follow up post vaccination, but this did not differ between  
72 vaccine and placebo arms, indicating that this reflected spontaneous cure rather than vaccine

73 efficacy. Immune monitoring using whole blood transcriptomics confirmed the previously  
74 reported ability of this vaccine to induce immune responses in humans.

#### 75 **Implications of all the available evidence.**

76 This study indicates that as a stand-alone treatment, single dose vaccination with ChAd63-  
77 KH was unable to overcome the immune dysfunction that maintains persistent PKDL. A  
78 similar “high bar” has also been encountered in therapeutic vaccine trials for other persistent  
79 diseases. Given previous success with other forms of immunochemotherapy in PKDL, future  
80 therapeutic vaccine studies in PKDL might also benefit from combining ChAd63-KH  
81 vaccination with additional chemotherapy or immune modulation. The prophylactic efficacy  
82 of this vaccine against different types of leishmaniasis also remains to be evaluated.

83

84

#### 85 **Introduction**

86 Post kala azar dermal leishmaniasis (PKDL) is a chronic dermatological sequela associated  
87 with treatment for visceral leishmaniasis (VL; kala azar), but it may occur without a history  
88 of VL or even during treatment of VL (when it is known as para kala-azar dermal  
89 leishmaniasis). PKDL typically involves the face and later spreads to the extremities and  
90 trunk<sup>1-3</sup>. PKDL has often been confused with leprosy and because of its chronic but not  
91 debilitating nature, it is often tolerated by infected people who fail to seek treatment. Case  
92 rates for PKDL are intimately linked to the waxing and waning of VL incidence<sup>4</sup>. The VL  
93 elimination campaign in South Asia has served to focus attention on PKDL, as those with the  
94 disease have been shown to harbour parasites in their skin and be infectious to the sand fly  
95 vector. As such, people with PKDL may serve to maintain infection in inter-epidemic periods  
96 thus posing a threat to elimination<sup>5</sup>. Epidemiological modelling has demonstrated the value  
97 of a PKDL vaccine for mitigating this risk in a post-elimination era<sup>6</sup>. Recent calls to action

98 for VL elimination on the African continent also recognise the need to have effective means  
99 to control PKDL<sup>7</sup>. Drug regimens for PKDL are generally arduous, invasive and have  
100 multiple potential side effects<sup>8,9</sup>. PKDL can also be exacerbated by HIV, and such cases  
101 respond poorly to treatment<sup>10</sup>. New combination therapies have been evaluated and show  
102 promise both in reducing the burden of PKDL<sup>11</sup> and in treatment<sup>12</sup>, but there has been a  
103 strong and persistent argument for developing additional means of control including  
104 therapeutic vaccines<sup>13-15</sup>.

105

106 PKDL has several intriguing features epidemiologically, clinically and immunologically. VL  
107 is caused by infection with two species of the protozoan parasite *Leishmania*, namely *L.*  
108 *donovani* and *L. infantum*, yet PKDL is restricted to infection with *L. donovani* and found  
109 only in the Old World<sup>2</sup>. PKDL is also restricted within the geographical range of *L.*  
110 *donovani*, being found in Sudan and South Asia, but rarely in other countries in East Africa.  
111 PKDL typically occurs after treatment whether this be with pentavalent antimonials,  
112 amphotericin B, miltefosine and paromomycin/ antimonial combinations<sup>16</sup>. However, the  
113 onset of disease varies geographically, being rapid (weeks to months) in Sudan compared to  
114 delayed (often years) in South Asia. Clinical presentation also varies geographically and at  
115 different body sites, with various hypotheses, including UVB exposure, being put forward to  
116 explain differences in clinical presentation<sup>17,18</sup>. In Sudan, disease presents mainly as nodules  
117 and papules that in ~80% of cases self-resolve over several months<sup>8,19</sup>. In the remainder,  
118 lesions may persist often for years. In contrast, in South Asia cases can show hypopigmented  
119 macular lesions or be polymorphic, with both macular and nodular lesions. Immunological  
120 and histopathological differences have also been noted<sup>17,18,20-23</sup>. Collectively, these features  
121 suggest that PKDL is a heterogeneous disease, with implications for the development of new  
122 therapeutics.

123 Therapeutic vaccination against PKDL in Sudan has its historical roots in the use of first-  
124 generation vaccines for VL. Khalil and colleagues conducted Phase I/II randomised trials in  
125 volunteers with no history of VL and showed that two intradermal doses of autoclaved *L.*  
126 *major* (ALM) administered with Bacille Calmette-Guérin (BCG) was safe, well tolerated and  
127 immunogenic, as measured by skin test conversion<sup>24-26</sup>. However, no efficacy with regards  
128 protection against VL was observed. These studies were followed up by evaluation of alum-  
129 adjuvanted ALM + BCG, again demonstrating safety and immunogenicity<sup>27,28</sup>. This latter  
130 formulation was subsequently evaluated as a potential therapeutic in PKDL patients with  
131 persistent disease. The study enrolled 30 patients randomised to receive Alum-ALM+BCG +  
132 sodium stibogluconate (SSG) vs. SSG alone and reported a cure rate at 60 days of 87% in the  
133 combined therapy group vs 53% in the SSG alone group (SSG + vaccine efficacy=71%, 95%  
134 CI for risk ratio 0.7-1.16)<sup>29</sup>. Based on these encouraging results, we evaluated the safety  
135 and immunogenicity of ChAd63-KH, a new adenoviral vaccine incorporating two well-  
136 documented vaccine candidate antigens that was designed to have potential as a pan-  
137 leishmaniasis vaccine<sup>30</sup>. This open label Phase IIa therapeutic trial in persistent PKDL  
138 patients (LEISH2a; ClinicalTrials.gov ID: NCT02894008) was designed as a “window of  
139 opportunity” study, where vaccine was administered alone, and standard of care provided as  
140 needed after a 90 day follow up period<sup>31</sup>. The study confirmed that ChAd63-KH was both  
141 safe and immunogenic in this patient group, opening the way for the randomised controlled  
142 efficacy trial reported here.

143

144

## 145 **Methods**

146 *Ethics statement*

147 The LEISH2b study (Clinicaltrials.gov ID: NCT03969134) was approved by the Sudan  
148 National Medicines and Poisons Board, and the Ethical Review Committees of the Institute  
149 of Endemic Diseases, University of Khartoum and the Department of Biology, University of  
150 York. LEISH2b was sponsored by the University of York. The study was conducted  
151 according to the principles of the current revision of the Declaration of Helsinki 2008 and  
152 ICH guidelines for GCP (CPMP/ICH/135/95). All participants provided written informed  
153 consent before enrolment. Consent forms are available accompanying the published protocol  
154 <sup>32</sup>.

155

### 156 *Study design and participants*

157 LEISH2b was a randomized, double blind, placebo-controlled therapeutic trial designed to  
158 evaluate the safety and efficacy of therapeutic vaccination with the investigational vaccine  
159 ChAd63-KH. The initial study design allowed for recruitment of 100 participants diagnosed  
160 with PKDL aged between 18-50 (adults) or 12-17 (adolescents) and with persistent PKDL of  
161 greater than six months duration. Full details of the inclusion and exclusion criteria are  
162 provided in the published Protocol <sup>32</sup>. Participants were recruited from an endemic area in  
163 Gedaref state, Sudan and all study procedures were conducted at the Professor El-Hassan's  
164 Centre for Tropical Medicine, Dooka, Sudan. Clinical monitoring of the study was  
165 performed under contract by ClinServ (<http://www.clinerv.net>). An independent Data Safety  
166 and Monitoring Board (DSMB) was established and met throughout the study period. The  
167 DSMB Charter is available accompanying the published protocol <sup>32</sup>.

168

### 169 *Eligibility criteria*

170 Full inclusion and exclusion criteria are provided in the Protocol <sup>32</sup>. Key inclusion criteria  
171 included: age 12 to 50 years on the day of screening; females must be unmarried, single, or

172 widowed; willing and able to give written informed consent/assent; uncomplicated PKDL of  
173  $\geq$  six month duration; otherwise good health; negative for malaria on blood smear;  
174 *Leishmania* PCR positive on the screening skin biopsy; willing to undergo urinary pregnancy  
175 tests (females only). Key exclusion criteria included: mucosal or conjunctival PKDL;  
176 treatment for PKDL within 21 days; negative rK39 strip test; receipt of a live attenuated  
177 vaccine within 60 days or other vaccine within 14 days of screening; history of allergic  
178 disease or reactions to vaccines or their components; history of severe local or general  
179 reaction to vaccination; fever  $\geq 39.5^{\circ}\text{C}$  within 48 hours, anaphylaxis, bronchospasm,  
180 laryngeal oedema, collapse, convulsions or encephalopathy within 48 hours; pregnancy, less  
181 than 12 weeks postpartum, lactating, or willingness/intention to become pregnant during the  
182 study and for three months following vaccination (females only); seropositive for hepatitis B  
183 surface antigen (HBsAg) or Hepatitis C (antibodies to HCV); tuberculosis, leprosy, or  
184 malnutrition (malnutrition in adults defined as a BMI  $<18.5$ , and in children and adolescents  
185 (eight-17yrs) as a Z score cut-off value of  $<-2$  SD).

186

### 187 *Vaccine and study procedures*

188 As described previously<sup>31</sup>, ChAd63-KH encodes two leishmanial proteins (KMP-11 and  
189 HASPB1) and was manufactured to cGMP by Advent Srl. (Pomezia, Italy; lot B0004;  
190  $7.5 \times 10^{10}$  viral particles (vp) per ml). ChAd63-KH was administered as a single dose in 1ml  
191 volume intramuscularly into the deltoid muscle. Participants were monitored in hospital for 7  
192 days post vaccination and thereafter as out-patients on days 21, 42, 90 and 120 post  
193 vaccination. Recruitment occurred over four rounds, punctuated by a revolution, a pandemic  
194 and a coup. Meetings of the independent DSMB were held at the end of each round of  
195 recruitment. Participants were evaluated for clinical response at day 42 and day 90. Those  
196 with less than 75% improvement at day 90 were offered standard treatment (AmBisome<sup>®</sup>;



197 2.5mg/kg/day for 20 days). If improvement was between 75-90%, they were offered  
198 conservative treatment or AmBisome®, and those with greater than or equal to 90% clinical  
199 improvement were deemed to not require further treatment (and scored as clinical cure).  
200 Some participants defaulted from scheduled visits and were evaluated and treated at  
201 unscheduled visits based on their availability. Decisions to treat and evaluation of PKDL  
202 were performed by two clinicians. Clinical grade of PKDL was also recorded before and  
203 after vaccination using the 4-point grading system described previously<sup>33</sup>.

204

#### 205 *Randomisation and Blinding*

206 A computer generated (Stata 16) randomisation list was prepared by the trial statistician,  
207 allocating participants 1:1 to either the active or placebo injection, using randomly permuted  
208 blocks, stratified by age group (adult or adolescent). The randomisation allocation was  
209 communicated to pharmacy staff at the study site through pre-prepared, sealed envelopes  
210 with only external sequential participant numbers. During the trial, adults were found to be  
211 more difficult to recruit, and the initial aim of an equal number of adolescents and adults in  
212 the trial was not feasible. However, the number of available randomisation envelopes in the  
213 Sudan was limited for each age group. Therefore, once allocations for the adolescent group  
214 had been used up, allocations for the adult stratum were used in order of presentation  
215 irrespective of age group, thus creating a single, unstratified randomised sample.

216

217 The vaccine and placebo injections were prepared in blacked out syringes labelled only with  
218 the participant identification number. The participants and clinical investigators (who  
219 administered the IMP and conducted the study follow-up) were blinded as to which injection  
220 participants received. The trial statistician (who generated the randomisation list), trial  
221 coordinator (who prepared sealed envelopes according to the randomisation list), assistant

222 pharmacist (who prepared the IMP) and study nurse (who delivered the IMP to the clinical  
223 investigators) were not blind to the treatment allocation.

224

### 225 *Outcomes*

226 Primary outcome measures were i) safety as recorded as adverse events from clinical  
227 examination and evaluation of blood biochemistry and haematology, and ii) efficacy, as  
228 determined by the proportion of participants reaching  $\geq 90\%$  improvement in clinical disease.  
229 Secondary outcomes included trajectory of lesion improvement and measures of vaccine  
230 induced immune response. Planned immune analyses included whole blood transcriptomics  
231 and analysis of peripheral lymphocyte responses (Ab and IFN $\gamma$  ELISpot). Peripheral  
232 lymphocyte and antibody responses could not be measured due to sample loss resulting from  
233 the military conflict in Sudan.

234

### 235 *Statistical analysis*

236 The statistical analysis plan is provided in the Supplementary Data file. A total sample size  
237 of 100 (randomly assigned 1:1 to be vaccinated with ChAd63-KH or placebo) was  
238 determined to be sufficient to detect an increase of  $\geq 25\%$  in the proportion of participants  
239 achieving clinical cure, assuming 90% power, 5% statistical significance, a spontaneous  
240 clearance rate of  $\leq 2\%$  and loss to follow-up of  $\leq 5\%$  (Fisher's exact test). Baseline  
241 characteristics were summarised descriptively. Continuous measures are reported as mean,  
242 standard deviation, median, and range while categorical data are reported as counts and  
243 percentages. Number of local and systemic AEs per participant are presented as median,  
244 minimum, maximum and IQR. The median number of AEs per participant (separately for  
245 local and systemic events) were compared between groups using the Mann-Whitney U test.  
246 Primary efficacy outcome of  $>90\%$  clinical improvement between the two arms was

247 evaluated using relative risk ratio (RR) with statistical significance determined by Fisher's  
248 Exact Test. Event numbers were too low to allow for an adjusted regression analysis.  
249 Comparison of categorical data across groups was analysed using Fisher's Exact Test.  
250 Analyses were performed using Stata v18, Rv4.3.2 or Prism 10 for macOS (v10.1.1;  
251 GraphPad).

252

### 253 *Whole blood transcriptomic analysis*

254 Whole blood samples (2.5 ml) were collected into PAXgene tubes immediately prior to  
255 vaccination and at 1 day post vaccination. All reagents and equipment for these analyses were  
256 supplied by ThermoFisher Scientific and processes carried out per manufacturers' protocols,  
257 unless otherwise stated. Total RNA was extracted using the PAXgene Blood RNA kit  
258 (PreAnalytiX, QIAGEN). RNA was quantified using the Qubit® 2.0 Fluorometer with the  
259 RNA HS Assay Kit. ~50 ng of total RNA was used to construct sequencing libraries with the  
260 Ion AmpliSeq™ Transcriptome Human Gene Expression Kit. Libraries were barcoded,  
261 purified with 2.5 X Agencourt AMPure XP Magnetic Beads (Beckman Coulter) and then  
262 quantified using Ion Library TaqMan Quantitation Kit on a QuantStudio 5. Libraries were  
263 diluted to a concentration of about 50 pMol and pooled in groups of 8 for sequencing on Ion  
264 PI Chips. Chips were loaded using the Ion Chef System and the IonPI Hi-Q Chef Kit.  
265 Sequencing was performed on an Ion Proton Sequencer using Ion PI Hi-Q Sequencing 200  
266 Kit.

267

268 Differential gene expression analysis was performed using DeSeq2. After count data  
269 normalization, differential gene expression analysis was performed using pooled day 0 data  
270 from the two study cohorts as the baseline for all contrasts. Enrichment of blood transcription  
271 modules at each time point in the different groups was assessed with the tmod R package,

272 using as an input the lists of differentially expressed genes ranked by the p-value after  
273 multiple test correction, as computed by DeSeq2. Significance of module enrichment was  
274 assessed using the CERNO statistical test (a modification of Fisher’s combined probability  
275 test) and corrected for multiple testing using the Benjamini–Hochberg correction.

276

### 277 *Role of Funders*

278 The funders played no part in study design, data collection, analysis, interpretation, writing or  
279 decision to publish. All authors had full access to study data and final responsibility for the  
280 decision to submit for publication.

281

282

## 283 **Results**

### 284 *Site Initiation and recruitment*

285 The LEISH2b study was conducted over approximately four years, punctuated by periods of  
286 significant challenge that resulted in temporary trial suspensions. The site initiation visit  
287 (SIV), attended by all field site personnel, trial monitors and trial staff from the Universities  
288 of Khartoum and York took place in August 2019 in Addis Ababa, due to a popular uprising  
289 and deteriorating security situation in Sudan. Recruitment began on 4<sup>th</sup> April 2020 and  
290 continued through June 2020 with 17 participants recruited in this period. Recruitment was  
291 then paused due to the SARS-CoV-2 pandemic. The second round of recruitment took place  
292 between December 2020 and February 2021, enrolling 28 participants. A third round of  
293 recruitment took place in April and May 2021 adding 23 participants. Delayed by a military  
294 coup, the final round of recruitment (May to June 2022) added 18 more, bringing the total to  
295 86 participants. Following discussion with the LEISH2b DSMB, a meeting of the Trial  
296 Steering Group with the funders was convened. All attendees agreed that recruitment should

297 halt at 86 participants due to logistical difficulties in completing the trial prior to expiry of the  
298 IMP and with the onset of further military clashes. 75/86 (87%) of enrolled participants  
299 completed the study to day 90 post vaccination, with last patient, last visit on 20th Sept 2022.  
300 Missed visits and losses to follow up were due to occupational priorities. A further day 120  
301 visit was arranged to allow follow up of any drug treatment provided at the completion of the  
302 study. A summary of study recruitment is provided in the CONSORT diagram (**Figure 1**).

303

#### 304 *Study population*

305 Demographics and PKDL grading of the 86 participants enrolled in this study are shown in  
306 **Table 1**. All participants had PKDL for 6mths duration or longer with the majority (88%)  
307 graded as either PKDL grade 1 or 2 (**Table 1 and Table S1**). Day 90 visits were completed  
308 by 75 (87%) participants (n=11 missed this time point or had been lost to follow-up; **Figure**  
309 **1**). As per protocol, participants were offered standard of care (AmBisome®) at day 90 if  
310 clinical improvement was less than 90%. Overall, 26/86 (30%) elected to receive treatment  
311 (8/20 adults; 18/66 adolescents) and these participants remain in long term follow up to  
312 confirm drug effectiveness.

313

#### 314 *Safety outcomes*

315 There were 70 (25 local and 45 systemic) AEs reported by 43 participants during the study  
316 split 1.6:1 between vaccine and placebo groups (**Tables S2-S5**). Average number of local  
317 AEs per participant were 0.30 in the vaccine vs 0.29 in the placebo arm (median of 0 in both  
318 arms), and systemic AEs per participant were 0.68 in the vaccine vs 0.36 in the placebo arm  
319 (median of 0 in both arms). Event numbers did not significantly differ between arms (Mann-  
320 Whitney U  $p=0.921$  and  $p=0.501$  respectively). AEs were limited to grade 1 and 2, with no  
321 grade 3, SAEs or SUSARs reported. All local and systemic AEs were deemed to be not

322 serious and recovered. 44 AEs (25 local and 19 systemic) were considered possibly-,  
323 probably-, or definitely related to vaccination again showing a bias towards vaccine  
324 recipients (**Figure 2**). These included itch, pain or soft swelling at the injection site,  
325 headache, vomiting, fever and general muscle pain. Medication was not required for any of  
326 the local AEs but paracetamol (for headache, chills, fever) and chlorphenamine (for whole  
327 body itch) were prescribed for systemic AEs. No clinically relevant changes in blood  
328 biochemistry or haematology were observed. The most common systemic AE unrelated to the  
329 study was malaria (16 clinical episodes, 15 patients). One case of thrombocytopenia was  
330 recorded but deemed unrelated to vaccination (occurring in the placebo group).

331

### 332 *Clinical outcomes*

333 The per protocol primary outcome measure was 90% or greater improvement in clinical  
334 PKDL as determined by two clinical assessors. Of the 75 participants that completed the  
335 study to d90 (39F, 36M; **Table S1**), 6/40 (15%; 2F, 4M) and 4/35 (11%; 3F, 1M) in the  
336 vaccine and placebo arms respectively reached this threshold (RR 1.31 [95% CI, 0.40 to  
337 4.28],  $p=0.742$ ). To explore whether there was any vaccine effect at lower levels of  
338 improvement, we calculated the proportion of participants that attained 25, 50, 75 and 90% of  
339 improvement over time of follow up, and the trajectory of recovery appeared very similar  
340 between arms (**Figure 3a**). Of note, all participants that reached the primary outcome did so  
341 between day 42 and d90 of follow up. The secondary outcome of PKDL grading (Grade 1 to  
342 Grade 4) was evaluated as PKDL severity is often used to monitor disease status<sup>33</sup>. Grade  
343 distributions improved only marginally over time and were similar between arms ( $p=0.36$ ,  
344  $p=0.53$  and  $p=0.38$  for days 21, 42 and 90 respectively; Fisher's exact test; **Figure 3b**).

345

346 As duration of PKDL has been suggested to influence cure rate <sup>19</sup>, we additionally obtained  
347 prior duration in months data for a sub-group of 57/75 participants completing day 90 FU (45  
348 adolescents, 12 adults; 33F, 24M). We stratified this subgroup into two classes based on  
349 duration of PKDL (<18 mths: median 11 months, range 6-11 months; n = 26 and ≥18mths,  
350 median 36 months, range 18 - 120 months, n= 31) and evaluated whether there was any  
351 difference in the proportion of patients reaching a conservative 50% improvement. In the  
352 <18 mths duration class, 6/11 receiving vaccine and 6/15 receiving placebo reached this  
353 threshold compared to 5/19 and 5/12 in the >18 mths duration class. Hence, duration of  
354 PKDL in this limited cohort did not appear to be associated with vaccine response or overall  
355 improvement.

356

357 Collectively, these analyses indicate that under the trial conditions employed, ChAd63-KH  
358 lacked efficacy as a single treatment in patients with persistent PKDL in Sudan.

359

### 360 *Whole blood transcriptome prior to and after vaccination*

361 We used whole blood transcriptional analysis (WBTA) to confirm vaccine reactogenicity and  
362 capacity to induce immune responses in a subset of patients (n= 23 placebo and n= 27 Vx) for  
363 which PAXgene-collected blood samples were available for analysis. Compared to pre-  
364 vaccination, no differentially expressed genes (DEGs) were identified at day 1 post  
365 vaccination in patients receiving placebo (log<sub>2</sub>FC >1, adj p<0.05). In contrast in patients  
366 receiving ChAd63-KH, we identified 318 DEGs using this threshold (311 UP, 7 DOWN;  
367 **Table S6**). Using g-profiler, we annotated enriched terms associated with the response to  
368 ChAd63-KH, providing clear evidence of anti-viral, inflammatory, and immune response  
369 gene activation (**Figure 4a** and **Table S6**). To provide comparison with data from our  
370 previous Phase IIa study and responses to a range of other vaccines <sup>36</sup>, we next identified

371 transcriptional modules associated with vaccination<sup>37</sup>. In keeping with the above analysis  
372 and with our previous analysis of ChAd63-KH responsiveness in PKDL patients<sup>31</sup>, highly  
373 upregulated transcriptional modules included those associated with interferon responsiveness,  
374 dendritic cell and monocyte activation and antigen presentation (**Figure 4b** and **Table S6**).  
375 Out of 57 significantly enriched transcriptional modules, 31 were also enriched in the  
376 adolescent cohort of the LEISH2a study<sup>31</sup>. Given that only 2/50 of the patients for which  
377 transcriptomic data was available achieved the primary outcome of  $\geq 90\%$  clinical response, it  
378 was not possible to conduct a robust analysis to identify differentially expressed genes or  
379 modules associated with clinical cure.

380

381

## 382 **Discussion**

383 ChAd63-KH is a “third generation” DNA vaccine based on adenoviral delivery of a gene  
384 construct encoding two well-characterised *Leishmania* antigens. In a Phase IIb stand-alone  
385 therapeutic trial in Sudanese patients with persistent PKDL, we have confirmed safety of this  
386 vaccine. However, this study failed to demonstrate clinical efficacy when measured by  
387 clearance of PKDL lesions over a 90-day follow up period.

388

389 The study was conducted in Gedaref state, South-eastern Sudan against a backdrop of  
390 significant adversity. Over the study period, Sudan sequentially experienced a revolution, a  
391 pandemic, a coup and military conflict that remains ongoing to date. Nevertheless,  
392 throughout this period, the trial team were able to maintain most aspects of trial management  
393 and governance although considerable delays in recruitment and in the ability to undertake  
394 sample analysis occurred. Following consultation with the DSMB and trial sponsor, the  
395 decision was taken in November 2022 to curtail recruitment at 86 participants, short of the



396 100 originally proposed. Full data analysis for the primary clinical outcome is reported here,  
397 with additional sub-group analysis being reported where patient metadata or biological  
398 samples were incomplete (either due to sample loss or data inaccessibility).

399

400 The primary clinical outcome of the study was to determine whether a single administration  
401 of ChAd63-KH vaccine was able to induce  $\geq 90\%$  improvement of PKDL in Sudanese  
402 patients with persistent disease of  $\geq 6$  months duration. Our analysis of 75 patients that that  
403 completed follow up to day 90 indicated that this was not the case. Similarly, PKDL grade  
404 was not improved over this time in vaccinated patients compared to those receiving placebo.  
405 Relaxing the criterion for clinical response also did not reveal any significant vaccine effect  
406 or effect of duration of prior PKDL. Hence, we conclude that this Phase IIb clinical trial has  
407 not demonstrated efficacy of ChAd63-KH under the conditions tested.

408

409 It is therefore important to consider the premise on which this study was based and potential  
410 reasons why efficacy was not observed. The immunopathogenic mechanisms that result in  
411 the chronic dermal presentation of PKDL are not fully understood. Immunohistological  
412 analysis of biopsies from Sudanese PKDL patients have noted the presence of CD4<sup>+</sup> and  
413 CD8<sup>+</sup> T cells but their functional state has not been characterised. Granuloma formation is  
414 seen in some cases but the histopathological picture may not correspond with clinical  
415 outcome<sup>23</sup>. Keratinocyte IL-10 expression during VL was observed to be associated with  
416 later development of PKDL<sup>36</sup>, but the specific role of IL-10 in PKDL per se is not  
417 understood. In Indian PKDL, more extensive studies have characterised CCR4<sup>+</sup>CD8<sup>+</sup> T cells  
418 with a phenotype associated with exhaustion and immune regulation (PD-1<sup>hi</sup> IL-10<sup>+</sup>)<sup>20</sup>.  
419 Collectively, these findings lend support to the hypothesis underpinning this trial i.e. that  
420 enhancing CD8<sup>+</sup> T cell activation through vaccination may augment the ability of the host to

421 clear parasites/antigens and reduce local pathology. Although we were unable to study  
422 antigen specific T cell responses in this study due to loss of all frozen cells, our previous  
423 studies have indicated that KMP-11- and HASPB-specific CD8<sup>+</sup> IFN $\gamma$ <sup>+</sup> responses are induced  
424 in PKDL patients <sup>31</sup> and healthy volunteers <sup>30</sup> following ChAd63-KH vaccination. Given the  
425 comparability of the transcriptional response to vaccination seen in this and our other studies,  
426 we have no reason to suspect that similar T cell responses were not induced in this patient  
427 group. However, in the absence of efficacy, it is difficult to ascertain whether this CD8<sup>+</sup> T  
428 cell response was merely insufficient in magnitude to elicit a clinical response or whether a  
429 broader response (in terms of antigen specificity or immune response quality) might be  
430 needed to achieve a clinical response.

431

432 With their known ability to rapidly induce antigen specific CD8<sup>+</sup> T cells, adenoviral vectored  
433 vaccines have been extensively studied as potential therapeutic vaccines in cancer and  
434 chronic hepatitis B virus (HBV) infection. However, studies in these other diseases have to  
435 date also met with limited success. Whilst poor choice of immunogens was previously  
436 mooted as the explanation for therapeutic failure in cancer therapeutic trials, a common  
437 attribute of cancer and chronic viral disease is the development of a microenvironment that  
438 favours immune regulation or suppression. These changes often reflect the outcome of  
439 signalling through inhibitory checkpoint pathways (e.g. PD-1) or the induction of metabolic  
440 checkpoints such as IDO1, and it has been proposed that these disease-associated regulatory  
441 constraints on T cell function hinder vaccine efficacy. Experimental evidence to support this  
442 notion has been provided by Maini and colleagues who identified both NK cell and PD-1/PD-  
443 L1 signalling as negative regulators of HBV vaccine efficacy in animals <sup>37</sup>. Whilst evidence  
444 for such an immunoregulatory environment is less well established in PKDL and other forms  
445 of dermal leishmaniasis, some similarities to these other chronic diseases exist. For example,

446 both IDO1 and PD-L1 are abundant in chronic cutaneous leishmaniasis lesions resulting from  
447 *L. donovani* infection in Sri Lanka, with a reduction in PD-L1 expression predicting rate of  
448 cure after antimonial chemotherapy<sup>38</sup>. More recently, we have identified expression of these  
449 checkpoint molecules in CL patients infected with *L. (V.) braziliensis* and also in PKDL  
450 patients infected with *L. donovani* in India<sup>39</sup>. PKDL lesions are also enriched in M2  
451 macrophages<sup>21</sup> contributing to a lack of leishmanicidal capacity and an immunoregulatory  
452 environment. Hence, it is possible that the local inhibitory environment in the skin of  
453 persistent PKDL patients provides an obstacle to effector CD8<sup>+</sup> T cell function at this site. If  
454 this is indeed the case, it is likely that therapeutic vaccination in PKDL might also benefit  
455 from interventions that target regulatory pathways, such as those proposed in HBV<sup>37</sup>. Whilst  
456 studies using existing biologics or other clinically approved drugs might provide proof of  
457 concept data in PKDL, it is recognised that such high-cost adjunct therapies are unlikely to  
458 drive vaccine implementation in a lower- and middle-income country (LMIC) setting.  
459 Alternatively, vaccination in conjunction with anti-leishmanial chemotherapy should also be  
460 considered, given previous successes with immunochemotherapy in PKDL<sup>29</sup> and more recent  
461 evidence suggesting that such chemotherapy may also diminish the immunoregulatory  
462 environment in CL patients<sup>38</sup>.

463

464 We confirm in this study the potent ability of ChAd63-KH to induce innate responses  
465 characterised by antiviral gene signatures and dendritic cell and monocyte activation, with  
466 weaker representation of modules associated with neutrophil response and complement  
467 activation. The modules signatures observed are also in keeping with those observed in a  
468 multi-vaccine analysis conducted by Hagan et al<sup>40</sup> which included an adenoviral vaccine  
469 candidate (MRKAd5-HIV) and with our previous analysis of PKDL patients<sup>31</sup>. In the latter  
470 study, we observed that adolescents but not adults differentially expressed modules associated

471 with B cell activation (M47.0 and M47.1). However, we did not observe differential  
472 expression these modules in the current study, despite the patient subgroup studied for WBTA  
473 being mainly composed of adolescents. The reasons for this difference are currently  
474 unknown and are subject to ongoing investigation. We had also previously identified 11  
475 whole blood transcriptional modules predictive of 90% clinical cure, two of which were  
476 significantly differentially expressed between cure and non-cure participants (M139:  
477 lysosomal/endosomal proteins and M118.0: enriched in monocytes). Unfortunately, as only  
478 2/50 of the samples analysed here achieved this level of clinical cure, we are unable to  
479 confirm or otherwise the predictive value of these modules.

480

481 In addition to the loss of samples / data due to the ongoing conflict in Sudan and other issues  
482 discussed above, a limitation in study design was the evaluation of only one vaccination  
483 schedule. ChAd63-KH was administered as a stand-alone therapy using a single dose given  
484 intramuscularly. This approach was chosen for both scientific and pragmatic reasons.  
485 Extensive data derived from experimental studies and early phase human trials<sup>41</sup> and from  
486 late phase trials and real world evidence obtained during the SARS-CoV-2 pandemic<sup>42</sup> have  
487 indicated that repeat dosing with homologous adenovirus vaccines fails to significantly  
488 augment the CD8<sup>+</sup> T cell response. Though direct evidence is lacking, it seems likely that a  
489 similar outcome would occur with vaccination in PKDL patients. Pragmatically, single dose  
490 schedules have multiple benefits in a LMIC setting, including reducing logistical  
491 complexities and a reduction in cost, not least due to the savings from not requiring  
492 manufacture of two clinical grade vaccines. Similarly, intramuscular dosing is preferred in  
493 many clinical situations due to ease of administration and standardisation and tolerability but  
494 may not be the most appropriate route for eliciting skin homing CD8<sup>+</sup> T cells<sup>43</sup>. Thus, we  
495 cannot rule out that an efficacy signal may have been observed using a repeat dosing

496 schedule, by extending the period of follow up, by use of a heterologous prime-boost strategy  
497 <sup>41</sup> and / or by varying route of administration. Given the heterogeneity of clinical  
498 presentation and histopathology observed in PKDL, our data do not rule out the possibility of  
499 a therapeutic benefit from ChAd63-KH vaccination in either Sudanese patients with less  
500 persistent disease or in PKDL patients in South Asia. In addition, the prophylactic efficacy of  
501 this vaccine against different types of leishmaniasis remains to be evaluated. In conclusion,  
502 however, this Phase IIb study did not provide evidence to support progressing ChAd63-KH  
503 as a standalone therapeutic in Sudanese patients with persistent PKDL.

504

505

## 506 **Contributors**

507 Conceptualisation by EAGK, PMK, AML, CJNL, AMM and BMY. Clinical studies were  
508 conducted by BMY, EAGK, MO, AN, ETAE, A-AM, AJS, AMM, MA, ME, KS, and AEAM.  
509 Trial data collation and analysis was conducted by AK, RW, AMM, AML, CJNL, and PMK.  
510 Transcriptomic analysis was conducted by FS, CS, MN, GM, and PMK. Statistical analysis  
511 was conducted by AK and PMK. Writing original draft by PMK. Review & editing draft by  
512 CJNL, AML, AMM, BMY, RW and AK. Writing final draft by PMK. All authors read and  
513 approved the final version of the manuscript.

514

## 515 **Declaration of Interests**

516 PMK and CJNL are co-inventors of a patent that covers the gene insert used in ChAd63-KH.

517 No other conflicts of interest are declared.

518

## 519 **Acknowledgments**

520 The clinical trial was funded by a Wellcome Trust Translation Award (WT108518MA;  
521 <https://wellcome.ac.uk>). Additional support for transcriptomics studies was provided by a  
522 Wellcome Trust Senior Investigator Award (to PMK; WT104726) and by the TRANSVAC2  
523 program supported by the European Union's Horizon 2020 Research and Innovation  
524 programme under grant agreement No. 730964 (TNA1802-02; <https://www.transvac.org>).  
525 GSK is allowing York University to use the cell line ProCell92 (proprietary of GSK) for their  
526 adeno program. GSK had the opportunity to review the publication, but the content is solely  
527 the responsibility of the authors. The authors also express their gratitude to the DSMB (Dr  
528 Rob Davidson, Dr Koert Ritmeijer, Dr Wolfgang Stohr, and Prof Alaadin Ahmed) for their  
529 advice, continual support and encouragement and to all the study participants and their  
530 families.

531

## 532 **Data Sharing Statement**

533 Processed gene expression data are available as supplementary material. Raw gene  
534 expression data will be available from GEO on publication.

535

536

## 537 **References**

- 538 1. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Post kala-azar dermal  
539 leishmaniasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2001; **95**  
540 **Suppl 1**: S59-76.
- 541 2. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar  
542 dermal leishmaniasis. *The Lancet infectious diseases* 2003; **3**(2): 87-98.
- 543 3. Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar dermal  
544 leishmaniasis--an overview. *International journal of dermatology* 2010; **49**(8): 921-31.
- 545 4. Saurabh S, Roy P, Pandey DK, et al. Changing clinico-epidemiology of post-kala-azar  
546 dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states. *J Vector*  
547 *Borne Dis* 2020; **57**(2): 161-9.
- 548 5. Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in  
549 the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination  
550 Programme. *PLoS Negl Trop Dis* 2017; **11**(11): e0005877.

- 551 6. Le Rutte EA, Coffeng LE, Malvolti S, Kaye PM, de Vlas SJ. The potential impact of  
552 human visceral leishmaniasis vaccines on population incidence. *PLoS neglected tropical*  
553 *diseases* 2020; **14**(7): e0008468.
- 554 7. Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as  
555 a public health problem in east Africa: reflections on an enhanced control strategy and a call  
556 for action. *Lancet Glob Health* 2021; **9**(12): e1763-e9.
- 557 8. Musa AM, Khalil EA, Younis BM, et al. Treatment-based strategy for the  
558 management of post-kala-azar dermal leishmaniasis patients in the Sudan. *Journal of tropical*  
559 *medicine* 2013; **2013**: 708391.
- 560 9. Datta A, Podder I, Das A, Sil A, Das NK. Therapeutic Modalities in Post Kala-azar  
561 Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment  
562 Options. *Indian J Dermatol* 2021; **66**(1): 34-43.
- 563 10. Zijlstra EE. PKDL and other dermal lesions in HIV co-infected patients with  
564 Leishmaniasis: review of clinical presentation in relation to immune responses. *PLoS Negl*  
565 *Trop Dis* 2014; **8**(11): e3258.
- 566 11. Musa AM, Mbui J, Mohammed R, et al. Paromomycin and Miltefosine Combination  
567 as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A  
568 Randomized, Controlled, Multicountry Trial. *Clin Infect Dis* 2023; **76**(3): e1177-e85.
- 569 12. Younis BM, Musa AM, Monnerat S, et al. Safety and efficacy of  
570 paromomycin/miltefosine/liposomal amphotericin B  
571 2 combinations for the treatment of post-kala-azar dermal leishmaniasis in  
572 3 Sudan: a phase II, open label, randomized, parallel arm study. *PLoSNTD* 2024; **in press**.
- 573 13. Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE. Report of the Post  
574 Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June  
575 2012. *Parasites & vectors* 2013; **6**: 196.
- 576 14. Ghalib H, Modabber F. Consultation meeting on the development of therapeutic  
577 vaccines for post kala azar dermal leishmaniasis. *Kinetoplastid biology and disease* 2007; **6**:  
578 7.
- 579 15. Zijlstra EE, Kumar A, Sharma A, Rijal S, Mondal D, Routray S. Report of the Fifth  
580 Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14-16 May  
581 2018. *Parasites & vectors* 2020; **13**(1): 159.
- 582 16. Das VN, Pandey K, Singh D, Forwood C, Lal CS, Das P. Development of post-kala-  
583 azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge  
584 to elimination program in India. *Journal of postgraduate medicine* 2013; **59**(3): 226-8.
- 585 17. Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal  
586 leishmaniasis: an unresolved mystery. *Trends in parasitology* 2014; **30**(2): 65-74.
- 587 18. Ismail A, Khalil EA, Musa AM, et al. The pathogenesis of post kala-azar dermal  
588 leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a  
589 role? *Medical hypotheses* 2006; **66**(5): 993-9.
- 590 19. Musa AM, Khalil EA, Raheem MA, et al. The natural history of Sudanese post-kala-  
591 azar dermal leishmaniasis: clinical, immunological and prognostic features. *Ann Trop Med*  
592 *Parasitol* 2002; **96**(8): 765-72.
- 593 20. Mukherjee S, Sengupta R, Mukhopadhyay D, et al. Impaired activation of lesional  
594 CD8(+) T-cells is associated with enhanced expression of Programmed Death-1 in Indian  
595 Post Kala-azar Dermal Leishmaniasis. *Sci Rep* 2019; **9**(1): 762.
- 596 21. Mukhopadhyay D, Mukherjee S, Roy S, et al. M2 Polarization of Monocytes-  
597 Macrophages Is a Hallmark of Indian Post Kala-Azar Dermal Leishmaniasis. *PLoS Negl Trop*  
598 *Dis* 2015; **9**(10): e0004145.
- 599 22. Zijlstra EE. The immunology of post-kala-azar dermal leishmaniasis (PKDL).  
600 *Parasites & vectors* 2016; **9**: 464.

- 601 23. Ramesh V, Ramam M. Histopathology of Post Kala-azar Dermal Leishmaniasis.  
602 *Indian J Dermatol* 2020; **65**(6): 461-4.
- 603 24. Khalil EA, Elhassan AM, Zijlstra EE, et al. Safety and immunogenicity of an  
604 autoclaved *Leishmania major* vaccine. *East Afr Med J* 2000; **77**(9): 468-70.
- 605 25. Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclaved *Leishmania major* vaccine  
606 for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in  
607 Sudan. *Lancet* 2000; **356**(9241): 1565-9.
- 608 26. Satti IN, Osman HY, Daifalla NS, et al. Immunogenicity and safety of autoclaved  
609 *Leishmania major* plus BCG vaccine in healthy Sudanese volunteers. *Vaccine* 2001; **19**(15-  
610 16): 2100-6.
- 611 27. Kamil AA, Khalil EA, Musa AM, et al. Alum-precipitated autoclaved *Leishmania*  
612 major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety,  
613 skin-delayed type hypersensitivity response and dose finding in healthy volunteers.  
614 *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2003; **97**(3): 365-8.
- 615 28. Khalil EA, Musa AM, Modabber F, El-Hassan AM. Safety and immunogenicity of a  
616 candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved *Leishmania major*  
617 + BCG) in children: an extended phase II study. *Ann Trop Paediatr* 2006; **26**(4): 357-61.
- 618 29. Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-  
619 kala-azar dermal leishmaniasis: a novel approach to treatment. *Transactions of the Royal*  
620 *Society of Tropical Medicine and Hygiene* 2008; **102**(1): 58-63.
- 621 30. Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral  
622 leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.  
623 *PLoS Negl Trop Dis* 2017; **11**(5): e0005527.
- 624 31. Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-  
625 KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. *Mol Ther* 2021; **29**(7):  
626 2366-77.
- 627 32. Lacey C, Musa A, Khalil ET, et al. LEISH2b - A phase 2b study to assess the safety,  
628 efficacy, and immunogenicity of the *Leishmania* vaccine ChAd63-KH in post-kala azar  
629 dermal leishmaniasis. *Wellcome Open Res* 2022; **7**: 200.
- 630 33. Zijlstra EE, el-Hassan AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-  
631 azar dermal leishmaniasis. *Am J Trop Med Hyg* 1995; **52**(4): 299-305.
- 632 34. Therneau TM. A package for survival analysis in R. 2020. [https://CRAN.R-](https://CRAN.R-project.org/package=survival)  
633 [project.org/package=survival](https://CRAN.R-project.org/package=survival).
- 634 35. Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing Survival Curves  
635 using 'ggplot2'. <https://cran.r-project.org/web/packages/survminer/index.html>.
- 636 36. Gasim S, Elhassan AM, Khalil EA, et al. High levels of plasma IL-10 and expression  
637 of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of  
638 post-kala-azar dermal leishmaniasis. *Clin Exp Immunol* 1998; **111**(1): 64-9.
- 639 37. Maini MK. Tissue T cells in prophylactic and therapeutic vaccination responses.  
640 *Semin Arthritis Rheum* 2023; **63**: 152287.
- 641 38. Dey NS, Senaratne S, Somaratne V, et al. Early reduction in PD-L1 expression  
642 predicts faster treatment response in human cutaneous leishmaniasis. *J Clin Invest* 2021;  
643 **131**(22).
- 644 39. Dey NS, Dey S, Brown N, et al. IL-32 producing CD8<sup>+</sup> memory T cells  
645 and Tregs define the IDO1 / PD-L1 niche in human cutaneous leishmaniasis skin lesions.  
646 *medRxiv* 2024: 2024.01.02.23300281.
- 647 40. Hagan T, Gerritsen B, Tomalin LE, et al. Transcriptional atlas of the human immune  
648 response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.  
649 *Nat Immunol* 2022; **23**(12): 1788-98.




- 650 41. Hill AV, Reyes-Sandoval A, O'Hara G, et al. Prime-boost vectored malaria vaccines:  
651 progress and prospects. *Hum Vaccin* 2010; **6**(1): 78-83.
- 652 42. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of  
653 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults  
654 (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* 2021; **396**(10267):  
655 1979-93.
- 656 43. Rotrosen E, Kupper TS. Assessing the generation of tissue resident memory T cells by  
657 vaccines. *Nat Rev Immunol* 2023; **23**(10): 655-65.  
658

Characteristics		Vaccine		Placebo	
		N=44		N=42	
<b>Adults</b>		n=11		n=9	
		N	%	N	%
Sex	Male	8	73	6	67
	Female	3	27	3	33
PKDL grade	Grade 1	7	64	2	22
	Grade 2	3	27	5	56
	Grade 3	1	9	2	22
Age (years)	Mean (SD)	23.2 (5.98)		24.3 (7.18)	
	Median	21		22	
	Min, Max	18, 37		18, 40	
BMI	Mean (SD)	19.8 (1.92)		20.4 (1.67)	
	Median	20.1		19.6	
	Min, Max	16.2, 23.1		18.8, 23.3	
<b>Adolescents</b>		n=33		n=33	
		N	%	N	%
Sex	Male	17	52	15	45
	Female	16	48	18	55
PKDL grade	Grade 1	14	42	18	55
	Grade 2	15	45	12	36
	Grade 3	4	12	3	9
Age (years)	Mean (SD)	13.4 (1.78)		13.0 (1.49)	
	Median	12		12	
	Min, Max	12, 17		12, 17	
BMI	Mean (SD)	17.2 (2.85)		16.2 (2.01)	
	Median	16.9		15.9	
	Min, Max	12.4, 26.9		12.9, 20.7	

659  
660

661 **Table 1. Baseline characteristics of participants in Leish2b trial**




695

696  
697  
698  
699  
700  
701  
702  
703

**Figure 1. Study CONSORT diagram**


Solid boxes indicate participants to primary outcome at day 90 post vaccination. Treatment was offered per protocol from d90 (see text). Dotted boxes were outside trial window for primary outcome and represent scheduled follow to provide or monitor standard of care.



704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714

**Figure 2 Adverse events associated with the LEISH2b trial.**

Data are shown for local and systemic adverse events judged to be possibly, probably, likely, or definitely associated with vaccination. Data are shown as proportion of participants in the study (n=86). Only grade 1 AEs (mild, yellow; 26 vs. 17 events overall in vaccine vs placebo group) and grade 2 AEs (moderate; orange; 17 vs. 10 events overall in vaccine vs. placebo group) were observed. See Tables S2-S5 for full details.



741


742

743 **Figure 3. Clinical improvement in LEISH2b participants**


744 **a.** Clinical improvement by study arm (n = 40 and n = 35 for vaccine and placebo groups  
 745 respectively). Participants were categorised based on degree of improvement at different  
 746 times post vaccination (Vx). Colour key indicates improvement category. **b.** Distribution of  
 747 overall PKDL grades by study arm (n = 40 and n = 35 for vaccine and placebo groups  
 748 respectively). Participants were scored for PKDL grade at vaccination (day 0) and at  
 749 indicated days post vaccination (Vx). Colour key indicates grades. No significant differences  
 750 were detected at any time point or over time (Fisher's Exact test; see text).

751

a



b



752

753

754 **Figure 4. Whole blood transcriptomic analysis of vaccine response**

755 WBTA was conducted on blood drawn prior to and 1 day post vaccination. Data are shown  
756 for 50 vaccinated participants (19F, 31M; 9 adults, 41 adolescents). a. gProfiler analysis of

757 311 upregulated genes. Representative enriched pathways are numbered: 1. GO:0003725,  
758 double stranded RNA binding; 2. GO:0001730, 2'-5'-oligoadenylate synthetase activity; 3.  
759 GO:0042379, chemokine receptor binding; 4. GO:0019221, cytokine-mediated signalling  
760 pathway; 5. GO:0034097, response to cytokine; 6. GO:0045089, positive regulation of innate  
761 immune response; 7. GO:0051607, defence response to virus; 8. GO:0034341, response to  
762 type II interferon; 9. GO:0071357, cellular response to type I interferon; 10. REAC:R-HAS-  
763 1, cytokine signalling in immune system; 11. TF:M00772, IRF motif; 12. TF:M10080,  
764 STAT2 motif. Full details are provided in Table S6. **b.** Significantly enriched immune-related  
765 modules were identified applying the CERNO test on the adjusted p value-ranked lists of  
766 genes generated by DeSeq2 (see Table S6 for module gene lists). Bars represent proportion of  
767 significantly upregulated (red), downregulated (blue) or unchanged (grey) genes. The  
768 significance of module activation is proportional to the intensity of the bar, while the effect  
769 size is proportional to its width. Only top 35 modules (of 57; see Table S6) are shown for  
770 clarity. No DEGs and hence no modules were identified in patients receiving placebo.

771 **Supplementary information**

772 **Supplementary Data**

773 The *Supplementary Data\_ Tables S2-S5 and SAP file* contains the following:

- 774 1. Table S2 List of AEs by body system and preferred term
- 775 2. Table S3 List of AE severity by preferred term
- 776 3. Table S4 List of non-serious AEs
- 777 4. Table S5 List of vital signs and laboratory tests
- 778 5. Leish2b statistical analysis plan (SAP)

779

780 **Supplementary Data \_Table S1**

781 This *Excel file* supports Figure 3 and contains the following:

782 Raw data on PKDL improvement, prior PKDL duration, age, sex, subsequent treatment for  
783 all participants by coded ID.

784

785 **Supplementary Data \_Table S6**

786 This *Excel file* contains the following:

- 787 1. Raw counts table for 50 patients measured at day 0 and day 1 post vaccination
- 788 2. List of 311 upregulated genes in patients receiving ChAd63-KH (adj  $p < 0.05$ ; 2-fold  
789 change)
- 790 3. List of 7 down regulated genes in patients receiving ChAd63-KH (adj  $p < 0.05$ ; 2-fold  
791 change)
- 792 4. g-profiler output list of enriched terms for the 311 upregulated genes
- 793 5. Transcriptional module gene list (after Li et al (Ref 36))
- 794 6. Module analysis of response to ChAd63-KH